Zacks Investment Research
05 Mar 2026, 18:55 UTC · 35w ago
Impact · against what's priced in
Reblozyl's strong commercial traction and Phase 2 expansion into alpha-thalassemia provide a positive offset to Bristol Myers Squibb's legacy drug erosion. The data suggests a tangible growth floor and an expanded total addressable market that may outpace current top-line expectations.
No priced-in read yet
What the story claims
3 claims · scored −1 bearish … +1 bullish
Bristol Myers Squibb's Reblozyl has achieved annualized sales exceeding $2.3 billion.
More positive than 76% of claims this week
Reblozyl met primary and key secondary endpoints in a Phase 2 registrational study for anemia in adults with alpha-thalassemia.
Continue reading
5 related stories
Annualized sales of Reblozyl exceeding $2.3 billion and positive Phase 2 data for alpha-thalassemia provide a growth catalyst to mitigate the decline in legacy drug sales.
Read from the article alone
Scored by the NIS engine · methodology.
Search tags
More positive than 63% of claims this week
Bristol Myers Squibb is experiencing a significant decline in sales of its legacy drugs.
So whatRevenue erosion from legacy products creates a growth gap that the new portfolio must aggressively fill to maintain valuation.
More negative than 68% of claims this week
Which stocks this story touches
More positive than 78% of ticker scores this week
The company is seeing strong sales growth for Reblozyl and positive Phase 2 results for expansion into new markets.
More positive than 49% of ticker scores this week
Mentioned as evaluating a potential treatment in partnership with Takeda, though specific outcomes are not detailed.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
The Motley Fool
15h ago
[mutual] Keros Therapeutics is evaluating elritercept in partnership with Takeda.
+0.9%
Price agrees with the score
$62.91 vs $62.33 close before publication (Mar 4) · not market-adjusted
BMY chart →
